Israel - English - Ministry of Health

pfizer pharmaceuticals israel ltd - pneumococcal polysaccharide serotype 1; pneumococcal polysaccharide serotype 14; pneumococcal polysaccharide serotype 18c; pneumococcal polysaccharide serotype 19 f; pneumococcal polysaccharide serotype 19a; pneumococcal polysaccharide serotype 23f; pneumococcal polysaccharide serotype 3; pneumococcal polysaccharide serotype 4; pneumococcal polysaccharide serotype 5; pneumococcal polysaccharide serotype 6a; pneumococcal polysaccharide serotype 6b; pneumococcal polysaccharide serotype 7f; pneumococcal polysaccharide serotype 9v - suspension for injection - pneumococcal polysaccharide serotype 23f 2.2 mcg / 0.5 ml; pneumococcal polysaccharide serotype 19 f 2.2 mcg / 0.5 ml; pneumococcal polysaccharide serotype 14 2.2 mcg / 0.5 ml; pneumococcal polysaccharide serotype 9v 2.2 mcg / 0.5 ml; pneumococcal polysaccharide serotype 7f 2.2 mcg / 0.5 ml; pneumococcal polysaccharide serotype 6b 4.4 mcg / 0.5 ml; pneumococcal polysaccharide serotype 5 2.2 mcg / 0.5 ml; pneumococcal polysaccharide serotype 4 2.2 mcg / 0.5 ml; pneumococcal polysaccharide serotype 1 2.2 mcg / 0.5 ml; pneumococcal polysaccharide serotype 3 2.2 mcg / 0.5 ml; pneumococcal polysaccharide serotype 6a 2.2 mcg / 0.5 ml; pneumococcal polysaccharide serotype 18c 2.2 mcg / 0.5 ml; pneumococcal polysaccharide serotype 19a 2.2 mcg / 0.5 ml - pneumococcus, purified polysaccharides antigen conjugated - pneumococcus, purified polysaccharides antigen conjugated - active immunisation for the prevention of invasive disease, pneumonia and acute otitis media caused by streptococcus pneumoniae in infants, children and adolescents from 6 weeks to 17 years of age.active immunisation for the prevention of invasive disease and pneumonia caused by streptococcus pneumoniae in adults ≥18 years of age and the elderly

Australia - English - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme (australia) pty ltd - pneumococcal purified capsular polysaccharides, quantity: 50 microgram/ml - injection, solution - excipient ingredients: water for injections; phenol; sodium chloride - pneumovax 23 is indicated for immunisation of individuals in the following situations: all individuals over the age of 65 years; individuals with asplenia, either functional or anatomical, including sickle cell disease, in persons more than 2 years of age; where possible the vaccine should be given at least 14 days before splenectomy; immunocompromised patients at increased risk of pneumococcal disease (eg patients with hiv infection before the development of aids, nephrotic syndrome, multiple myeloma, lymphoma, hodgkin's disease and organ transplantation); aboriginal and torres strait islander people over 50 years of age; immunocompetent persons at increased risk of complications from pneumococcal disease because of chronic illness (eg chronic cardiac, renal or pulmonary disease, diabetes mellitus, alcoholism and cirrhosis); patients with cerebrospinal fluid leaks. in australia, the national health and medical research council (nhmrc) currently recommends the vaccination of tobacco smokers with the 23-valent polysaccharide pneumococcal vaccine. pneumovax 23 is indicated for immunisation only against pneumococcal disease caused by those pneumococcal types included in the vaccine. effectiveness of the vaccine in the prevention of pneumococcal pneumonia and pneumococcal bacteremia has been demonstrated. in australia, the national health and medical research council (nhmrc) currently recommeds the vaccination of tabacco smokers with the 23-valent polysaccharide pneumococcal vaccine. pneumovax 23 will not prevent disease caused by capsular types of pneumococcus othar those contained in the vaccine.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - pneumococcal purified capsular polysaccharides, quantity: 2.2 microgram; pneumococcal purified capsular polysaccharides, quantity: 4.4 microgram - injection, suspension - excipient ingredients: aluminium phosphate; water for injections; polysorbate 80; diphtheria crm197 protein; succinic acid; sodium chloride - active immunisation for the prevention of pneumococcal disease caused by streptococcus pneumoniae serotypes 1, 3, 4, 5, 6a, 6b, 7f, 9v, 14, 18c, 19a, 19f and 23f in adults and children aged more than 6 weeks of age. the use of prevenar 13 should be guided by official recommendations.

Ireland - English - HPRA (Health Products Regulatory Authority)

merck sharp & dohme ireland (human health) limited - pneumococcal vaccine - solution for injection in pre-filled syringe - 25 mcg/0.5 millilitre(s) - pneumococcal vaccines; pneumococcus, purified polysaccharides antigen

Ireland - English - HPRA (Health Products Regulatory Authority)

merck sharp & dohme ireland (human health) limited - pneumococcal vaccine - solution for injection - 25mcg/0.5 millilitre(s) - pneumococcal vaccines; pneumococcus, purified polysaccharides antigen

Malta - English - Medicines Authority

merck sharp & dohme b.v. waarderweg 39, haarlem noord-holland, 2031 bn, netherlands - pneumococcal polysaccharide, serotype, conjugated to, crm, b conjugated, to crm, f conjugated, n conjugated, v conjugated, a conjugated - solution for injection in a pre-filled syringe - pneumococcal polysaccharide serotype 3 conjugated to crm197 25 µg pneumococcal polysaccharide serotype 5 conjugated to crm197 25 µg pneumococcal polysaccharide serotype 6b conjugated to crm197 25 µg pneumococcal polysaccharide serotype 7f conjugated to crm197 25 µg pneumococcal polysaccharide serotype 8 conjugated to crm197 25 µg pneumococcal polysaccharide serotype 9n conjugated to crm197 25 µg pneumococcal polysaccharide serotype 9v conjugated to crm197 25 µg pneumococcal polysaccharide serotype 10a conjugated to crm197 25 µg pneumococcal polysaccharide serotype 11a conjugated to crm197 25 µg pneumococcal polysaccharide serotype 12f conjugated to crm197 25 µg pneumococcal polysaccharide serotype 14 conjugated to crm197 25 µg pneumococcal polysaccharide serotype 15b conjugated to crm197 25 µg pneumococcal polysaccharide serotype 17f conjugated to crm197 25 µg pneumococcal polysaccharide serotype 17f conjugated to crm197 25 µg pneumococcal polysaccharide serotype 19f conjugated to crm197 25 µg pneumococcal polysaccharide serotype 19a conjugated to crm197 25 µg pneumococcal polysaccharide serotype 20 conjugated to crm197 25 µg pneumococcal polysaccharide serotype 22f conjugated to crm197 25 µg pneumococcal polysaccharide serotype 23f conjugated to crm197 25 µg pneumococcal polysaccharide serotype 33f conjugated to crm197 25 µg pneumococcal polysaccharide serotype 1 conjugated to crm197 25 µg pneumococcal polysaccharide serotype 2 conjugated to crm197 25 µg - vaccines

Uganda - English - National Drug Authority

serum institute of india pvt ltd - pneumococcal saccharide for serotype 1, 5, 6a, 7f, 9v, 14, 19a, 19f and 23f + saccharide for serotype 6b - parenteral ordinary vials - (2 mcg of pneumococcal saccharide for serotype 1, 5, 6a, 7f, 9v, 14, 19a, 19f and 23f + 4 mcg of saccharide for serotype 6b)/ do

Australia - English - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - pneumococcal purified capsular polysaccharides -

Malta - English - Medicines Authority

central procurement & supplies unit - pneumococcal polysaccharide, serotype, f conjugated, to crm - solution for injection - pneumococcal polysaccharide serotype 23f conjugated to crm197 25 microgram(s) - vaccines

Malta - English - Medicines Authority

central procurement & supplies unit ub002 industrial estate, san gwann sgn 3000, malta - pneumococcal polysaccharide, serotype, conjugated to, crm, b conjugated, to crm, f conjugated, n conjugated, v conjugated, a conjugated, c conjugated - solution for injection - pneumococcal polysaccharide serotype 1 conjugated to crm197 50 µg/ml pneumococcal polysaccharide serotype 2 conjugated to crm197 50 µg/ml pneumococcal polysaccharide serotype 3 conjugated to crm197 50 µg/ml pneumococcal polysaccharide serotype 4 conjugated to crm197 50 µg/ml pneumococcal polysaccharide serotype 5 conjugated to crm197 50 µg/ml pneumococcal polysaccharide serotype 6b conjugated to crm197 50 µg/ml pneumococcal polysaccharide serotype 7f conjugated to crm197 50 µg/ml pneumococcal polysaccharide serotype 8 conjugated to crm197 50 µg/ml pneumococcal polysaccharide serotype 9n conjugated to crm197 50 µg/ml pneumococcal polysaccharide serotype 9v conjugated to crm197 50 µg/ml pneumococcal polysaccharide serotype 10a conjugated to crm197 50 µg/ml pneumococcal polysaccharide serotype 11a conjugated to crm197 50 µg/ml pneumococcal polysaccharide serotype 12f conjugated to crm197 50 µg/ml pneumococcal polysaccharide serotype 14 conjugated to crm197 50 µg/ml pneumococcal polysaccharide serotype 15b conjugated to crm197 50 µg/ml pneumococcal polysaccharide serotype 17f conjugated to crm197 50 µg/ml pneumococcal polysaccharide serotype 18c conjugated to crm197 50 µg/ml pneumococcal polysaccharide serotype 19f conjugated to crm197 50 µg/ml pneumococcal polysaccharide serotype 19a conjugated to crm197 50 µg/ml pneumococcal polysaccharide serotype 19f conjugated to crm197 50 µg/ml pneumococcal polysaccharide serotype 20 conjugated to crm197 50 µg/ml pneumococcal polysaccharide serotype 22f conjugated to crm197 50 µg/ml pneumococcal polysaccharide serotype 23f conjugated to crm197 50 µg/ml pneumococcal polysaccharide serotype 33f conjugated to crm197 50 µg/ml - vaccines